Kerendia (finerenone) — United Healthcare

Initial criteria

• Diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
• Urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g
• eGFR ≥ 25 mL/min/1.73 m2
• Used to reduce the risk of sustained eGFR decline OR end-stage kidney disease OR cardiovascular death OR non-fatal myocardial infarction OR hospitalization for heart failure
• Serum potassium level ≤ 5 mEq/L prior to initiating treatment
• Patient is on a stabilized dose and receiving concomitant therapy with a maximally tolerated angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril) OR maximally tolerated angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan) OR has allergy, contraindication, or intolerance to ACE inhibitors and ARB
• Patient is on a stabilized dose and receiving concomitant therapy with a SGLT2 inhibitor (e.g., Jardiance) OR has history of failure, contraindication, or intolerance to a SGLT2 inhibitor (e.g., Jardiance)

Reauthorization criteria

• Documentation of positive clinical response to therapy

Approval duration

12 months